Aristides Capital’s iShares Biotechnology ETF IBB Stock Holding History

Aristides Capital’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.78M	Buy	+30,406	New	+$5.23M	1.12%	23
2025 Q3	–	Sell	-28,467	Closed	-$3.6M	–	265
2025 Q2	$3.6M	Buy	+28,467	New	+$3.49M	0.72%	29
2024 Q3	–	Sell	-66,880	Closed	-$9.18M	–	273
2024 Q2	$9.18M	Buy	+66,880	New	+$8.93M	2.59%	5
2023 Q3	–	Sell	-63,773	Closed	-$8.1M	–	195
2023 Q2	$8.1M	Buy	+63,773	New	+$8.28M	3.29%	4
2022 Q3	–	Sell	-20,815	Closed	-$2.45M	–	166
2022 Q2	$2.45M	Buy	20,815 +7,515	+57%	+$892K	1.68%	15
2022 Q1	$1.73M	Sell	13,300 -5,500	-29%	-$716K	1.06%	19
2021 Q4	$2.87M	Buy	18,800 +7,000	+59%	+$1.08M	1.31%	16
2021 Q3	$1.91M	Sell	11,800 -36,750	-76%	-$6.18M	0.7%	29
2021 Q2	$7.95M	Buy	48,550 +44,150	+1,003%	+$6.8M	1.87%	7
2021 Q1	$662K	Buy	+4,400	New	+$699K	0.27%	67
2020 Q4	–	Sell	-6,020	Closed	-$815K	–	175
2020 Q3	$815K	Sell	6,020 -36,356	-86%	-$4.93M	0.57%	34
2020 Q2	$5.79M	Buy	+42,376	New	+$5.4M	4.37%	5

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Aristides Capital's IBB Position: Q2 2026 in Review

Aristides Capital opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 30,406 shares worth $5.78M. The stake represents 1.12% of the portfolio and ranks #23 among its holdings. This is a return to the name: Aristides Capital previously reported a position in IBB as recently as Q2 2025.

Aristides Capital first reported a position in IBB in Q2 2020 and has held it in 12 quarters since. The position peaked at $9.18M in Q2 2024. 957 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Aristides Capital held 30,406 shares of iShares Biotechnology ETF worth $5.78M as of Q2 2026.
iShares Biotechnology ETF was a new Aristides Capital position in Q2 2026.
iShares Biotechnology ETF made up 1.12% of Aristides Capital's portfolio in Q2 2026, its #23 holding.
Aristides Capital first reported a position in iShares Biotechnology ETF in Q2 2020 and has held it in 12 quarters since.
Aristides Capital's iShares Biotechnology ETF position peaked at $9.18M in Q2 2024.
957 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Aristides Capital's 13F filing for Q2 2026, filed 13 Aug 2026.